Abstract:Background and PurposeThere is emerging evidence for critical roles of epigenetic modifiers in development of inflammatory bowel disease (IBD). Protein arginine methyltransferase 2 (PRMT2) is responsible for methylation of arginine residues on histones and targets transcription factors critically involved in many cellular processes, including gene transcription, mRNA splicing, cell proliferation and differentiation. However, its role in colitis remains unknown. In this study, the role and underlying mechanisms of PRMT2 in colitis was studied. Experimental ApproachA mouse dextran sulfate sodium (DSS)-induced experimental colitis model was applied to study PRMT2 in colitis. Lentivirus induced PRMT2 silencing or overexpression in vivo was applied to address the role of PRMT2 in colitis. Detailed western blot and expression analysis was done to understand epigenetic changes induced by PRMT2 in colitis. Key ResultsPRMT2 is highly expressed in patients with IBD, inflamed colon of mice and TNF-α stimulated mice gut epithelial cells. PRMT2 overexpression aggravates while knockdown alleviates DSS-induced colitis in mice, suggesting that PRMT2 is a pivotal mediator of colitis development. Mechanistically, PRMT2 mediates colitis by increasing repressive histone mark H3R8 asymmetric methylation (H3R8me2a) at the promoter region of the suppressor of cytokine signaling 3 (SOCS3) promoter. Resultant inhibition of SOCS3 expression and SOCS3-mediated degradation of TNF receptor associated factor 5 (TRAF5) via ubiquitination led to elevated TRAF5 expression and TRAF5-mediated downstream NF-κB/MAPK activation. Conclusion and ImplicationsOur study demonstrates that PRMT2 acts as a transcriptional co-activator for proinflammatory genes during colitis. Hence targeting PRMT2 may provide a novel therapeutic approach for colitis.

Metabolic control of BRISC-SHMT2 assembly regulates immune signalling

Shp-2 Phosphatase Negatively Regulates The Trif Adaptor Protein-Dependent Type I Interferon And Proinflammatory Cytokine Production

Methyltransferase Setd2 Prevents T Cell-Mediated Autoimmune Diseases Via Phospholipid Remodeling

Molecular glues that inhibit deubiquitylase activity and inflammatory signalling

The BRISC Deubiquitinating Enzyme Complex Limits Hematopoietic Stem Cell Expansion by Regulating JAK2 K63-ubiquitination.

SIRT2 regulates high mobility group protein B1 nucleoplasmic shuttle and degradation via deacetylation in microglia

Selective Sequestration of STAT1 in the Cytoplasm Via Phosphorylated SHP-2 Ameliorates Murine Experimental Colitis

Tet2 Activity is Modulated by Sirt1-Mediated Protein Deacetylation: A Potential Therapeutic Target in Myelodysplastic Syndrome

Dynamic RBM47 ISGylation confers broad immunoprotection against lung injury and tumorigenesis via TSC22D3 downregulation

IGHMBP2 deletion suppresses translation and activates the integrated stress response

MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function

The deubiquitinating enzyme complex BRISC is required for proper mitotic spindle assembly in mammalian cells

Screening and Analysis of Potential Inhibitors of SHMT2

Protein arginine methyltransferase 2 (PRMT2) promotes dextran sulfate sodium‐induced colitis by inhibiting the SOCS3 promoter via histone H3R8 asymmetric dimethylation

Phosphatase SHP2-mediated Mitochondrial Homeostasis for the Resolution of Inflammation

SMRT Regulates Metabolic Homeostasis and Adipose Tissue Macrophage Phenotypes in Tandem

Molecular glues that inhibit specific Zn2+-dependent DUB activity and inflammation

Supplementary Table 1 from Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia

Study of SHMT2 Inhibitors and Their Binding Mechanism by Computational Alanine Scanning.

Macrophage fumarate hydratase restrains mtRNA-mediated interferon production

Multifaceted regulation of sirtuin 2 (Sirt2) deacetylase activity